Medicine
Tyruko 300 mg/15 mL injection
Tyruko 300 mg/15 mL injection is a prescription medicine containing Natalizumab for intravenous use, marketed by Sandoz, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store diluted TYRUKO solution refrigerated at 2°C to 8°C (36°F to 46°F).
Key facts
- Active ingredient (INN)
- Natalizumab
- Brand
- Tyruko
- Strength
- 300 mg/15 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 1 vial of 15 mL
- Marketing authorisation holder
- Sandoz
- Manufacturer
- Sandoz
- Origin register
- US FDA, United States
- Storage
- Store diluted TYRUKO solution refrigerated at 2°C to 8°C (36°F to 46°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L04AG03 Natalizumab
- HS code (indicative)
- 3002.15Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 November 2025
- Identifiers
- RxCUI 2725173, 2725180DailyMed set ID ef653c36-dd4b-4e71-9d2d-40b8fea24b67NDC 61314-543Application BLA761322
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, single-dose in 1 carton / 15 mL in 1 vial, single-dose | 61314-543-94 | Sandoz | 17 November 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Natalizumab 300 mg/15 mL injection.
Clinical summary
Natalizumab is an integrin receptor antagonist indicated for treatment of multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, among other approved uses. MedsAcross supplies Natalizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NatalizumabFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- TYSABRI prescribing information (Biogen) · U.S. National Library of Medicine, DailyMed
- Tysabri: European public assessment report (EPAR) · European Medicines Agency
- Tyruko: European public assessment report (EPAR) · European Medicines Agency
Need Tyruko 300 mg/15 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.